A phase II study of an outpatient three day VIP regimen [etoposide, ifosfamide, and cisplatin] with oral mesna for metastatic breast cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cisplatin; Etoposide; Ifosfamide; Mesna
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 11 Jun 2010 Biomarkers information updated
- 23 Feb 2010 Actual number of patients added to 36 as reported by ClinicalTrials.gov..
- 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.